Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-04-27

AUTHORS

Fatemeh Kalalinia, Fatemeh Elahian, Javad Behravan

ABSTRACT

PurposeABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines.MethodsThe cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay.ResultsTPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX.ConclusionThe results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2. More... »

PAGES

321-330

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9

DOI

http://dx.doi.org/10.1007/s00432-010-0893-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015219571

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20422426


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP Binding Cassette Transporter, Subfamily G, Member 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ATP-Binding Cassette Transporters", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Celecoxib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclooxygenase 2 Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Multiple", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Flow Cytometry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Enzymologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitoxantrone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetradecanoylphorbol Acetate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalalinia", 
        "givenName": "Fatemeh", 
        "id": "sg:person.01354672317.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elahian", 
        "givenName": "Fatemeh", 
        "id": "sg:person.01322665107.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322665107.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran", 
          "id": "http://www.grid.ac/institutes/grid.411583.a", 
          "name": [
            "Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Behravan", 
        "givenName": "Javad", 
        "id": "sg:person.01245756105.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245756105.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1202218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036542534", 
          "https://doi.org/10.1038/sj.onc.1202218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2867-5-30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003230076", 
          "https://doi.org/10.1186/1475-2867-5-30"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/aapsj070112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032127936", 
          "https://doi.org/10.1208/aapsj070112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1206938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036684086", 
          "https://doi.org/10.1038/sj.onc.1206938"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-04-27", 
    "datePublishedReg": "2010-04-27", 
    "description": "PurposeABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines.MethodsThe cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay.ResultsTPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX.ConclusionThe results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00432-010-0893-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1313647", 
        "issn": [
          "0171-5216", 
          "1432-1335"
        ], 
        "name": "Journal of Cancer Research and Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "137"
      }
    ], 
    "keywords": [
      "breast cancer cell lines", 
      "ABCG2 activity", 
      "cancer cell lines", 
      "COX-2", 
      "cell lines", 
      "mitoxantrone efflux", 
      "multidrug resistance", 
      "use of celecoxib", 
      "long-term treatment", 
      "efflux transporter ABCG2", 
      "cyclooxygenase-2 expression", 
      "COX-2 inducer", 
      "multidrug resistance phenotype", 
      "adjuvant therapy", 
      "greater stimulatory effect", 
      "cyclooxygenase-2", 
      "little inhibitory activity", 
      "MethodsThe cytotoxicity", 
      "probable causal link", 
      "effect of TPA", 
      "drug efflux", 
      "chemotherapeutic drugs", 
      "stimulatory effect", 
      "cancer treatment", 
      "celecoxib", 
      "MTT assay", 
      "transporter ABCG2", 
      "ABCG2", 
      "potential role", 
      "anticancer drugs", 
      "inhibitory activity", 
      "resistance phenotype", 
      "efflux", 
      "drugs", 
      "potential link", 
      "treatment", 
      "wide spectrum", 
      "TPA", 
      "causal link", 
      "patients", 
      "activity", 
      "therapy", 
      "tumors", 
      "cancer", 
      "inhibitors", 
      "role", 
      "cytotoxicity", 
      "inducer", 
      "phenotype", 
      "assays", 
      "effect", 
      "resistance", 
      "group", 
      "aim", 
      "years", 
      "expression", 
      "lines", 
      "study", 
      "regulation", 
      "recent years", 
      "use", 
      "development", 
      "members", 
      "link", 
      "tendency", 
      "results", 
      "growth", 
      "exploring", 
      "spectra", 
      "PurposeABCG2", 
      "flow cytometric mitoxantrone efflux", 
      "cytometric mitoxantrone efflux", 
      "ResultsTPA", 
      "MCF7-MX", 
      "drug efflux transporter ABCG2"
    ], 
    "name": "Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines", 
    "pagination": "321-330", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015219571"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00432-010-0893-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20422426"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00432-010-0893-9", 
      "https://app.dimensions.ai/details/publication/pub.1015219571"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_527.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00432-010-0893-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-010-0893-9'


 

This table displays all metadata directly associated to this object as RDF triples.

252 TRIPLES      22 PREDICATES      126 URIs      114 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00432-010-0893-9 schema:about N00734ce42aea47bd89a04c00400ea0a3
2 N044202dea0024223bace33fcc9f5c984
3 N1504e7c3c34340d8a782c3312236a1fa
4 N2c3f8dee29e84289a9c1ed2a0f2cf07f
5 N3577d8aad6b64dc586e6e351fe32423f
6 N365f08a88d864eeb8cd78cd59f028856
7 N3b25fe8190eb4495a68e6e5a9e3fd1bb
8 N48041db8ef04470aa831ff710cf2581d
9 N644a4351606841df92ece9f2d85eafef
10 N6de144d90d6f4e108cd558fea06a2a54
11 N6e6717700980423080374713c2b8cfe5
12 N718a9a651c4542a3a0a21137f3f06dd1
13 N91ba7dea361940b9845fd17b5634aaf8
14 N95eca40a206e461ab07e44668a0c3826
15 Na9d4b8c120c94a9c8c0ca38119bd3acb
16 Nb1216e3829b74312a5aa2cfc6d1aa1d9
17 Nb798cd2b01c04478ad35757baadb354e
18 Nc52563a953174dc0a3be37d65bf1ae6e
19 Nd5c5dcae4c644ce9a1d0ded13384d8fd
20 Ne7b33c22b54d4d6eb529d711b9cbfe02
21 Ne8ef4e029680445f8393bd87ace69792
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N76fd196b26da4571b134cf6ea3f1105a
25 schema:citation sg:pub.10.1038/sj.onc.1202218
26 sg:pub.10.1038/sj.onc.1206938
27 sg:pub.10.1186/1475-2867-5-30
28 sg:pub.10.1208/aapsj070112
29 schema:datePublished 2010-04-27
30 schema:datePublishedReg 2010-04-27
31 schema:description PurposeABCG2 (BCRP) implicated as a member of the multidrug resistance (MDR) proteins in tumors, mediating efflux of a wide spectrum of anticancer drugs. In recent years, there has been an increasing tendency toward the exploring of the potential link between cyclooxygenase-2 (COX-2) expression and development of multidrug resistance phenotype in patients with cancer. The aim of this study was to investigate the role of the COX-2 in modulating drug efflux by ABCG2 in a group of breast cancer cell lines.MethodsThe cytotoxicity of COX-2 inducer (TPA, tetradecanoyl phorbol acetate) and its inhibitor (celecoxib) was determined by an MTT assay. ABCG2 activity was measured by flow cytometric mitoxantrone efflux assay.ResultsTPA exhibited very little inhibitory activity in all cell lines, while long-term treatment with celecoxib significantly inhibited the growth of all cell lines. Furthermore, using mitoxantrone efflux assay was shown that TPA could increase ABCG2 activity in all the cell lines with the greatest stimulatory effects in MCF7-MX (more than 6 times the control level). It seemed that celecoxib inverted the effects of TPA on ABCG2 activity. This was more obvious in MCF7-MX.ConclusionThe results suggest a probable causal link between COX-2 and ABCG2 activity. The use of celecoxib for adjuvant therapy in cancer treatment may contribute to decreased resistance to chemotherapeutic drugs transported by ABCG2.
32 schema:genre article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N5f523e20fe224de6babf60e8f656d7bd
36 N870734c226a742b4987b71639ea168b7
37 sg:journal.1313647
38 schema:keywords ABCG2
39 ABCG2 activity
40 COX-2
41 COX-2 inducer
42 MCF7-MX
43 MTT assay
44 MethodsThe cytotoxicity
45 PurposeABCG2
46 ResultsTPA
47 TPA
48 activity
49 adjuvant therapy
50 aim
51 anticancer drugs
52 assays
53 breast cancer cell lines
54 cancer
55 cancer cell lines
56 cancer treatment
57 causal link
58 celecoxib
59 cell lines
60 chemotherapeutic drugs
61 cyclooxygenase-2
62 cyclooxygenase-2 expression
63 cytometric mitoxantrone efflux
64 cytotoxicity
65 development
66 drug efflux
67 drug efflux transporter ABCG2
68 drugs
69 effect
70 effect of TPA
71 efflux
72 efflux transporter ABCG2
73 exploring
74 expression
75 flow cytometric mitoxantrone efflux
76 greater stimulatory effect
77 group
78 growth
79 inducer
80 inhibitors
81 inhibitory activity
82 lines
83 link
84 little inhibitory activity
85 long-term treatment
86 members
87 mitoxantrone efflux
88 multidrug resistance
89 multidrug resistance phenotype
90 patients
91 phenotype
92 potential link
93 potential role
94 probable causal link
95 recent years
96 regulation
97 resistance
98 resistance phenotype
99 results
100 role
101 spectra
102 stimulatory effect
103 study
104 tendency
105 therapy
106 transporter ABCG2
107 treatment
108 tumors
109 use
110 use of celecoxib
111 wide spectrum
112 years
113 schema:name Potential role of cyclooxygenase-2 on the regulation of the drug efflux transporter ABCG2 in breast cancer cell lines
114 schema:pagination 321-330
115 schema:productId N1cfe38c438dc4af4a7d1ff8fee56d610
116 N2e06ed4ada3d45a3b43f51bbe9a20886
117 Nf90d29da54e64ad8a563571161482bcf
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015219571
119 https://doi.org/10.1007/s00432-010-0893-9
120 schema:sdDatePublished 2021-12-01T19:24
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N877eca01d96c41bea031824601877fd6
123 schema:url https://doi.org/10.1007/s00432-010-0893-9
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N00734ce42aea47bd89a04c00400ea0a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Drug Resistance, Neoplasm
129 rdf:type schema:DefinedTerm
130 N044202dea0024223bace33fcc9f5c984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Tetradecanoylphorbol Acetate
132 rdf:type schema:DefinedTerm
133 N0d5bc583ea394cee9a57a6c0012a89f2 rdf:first sg:person.01322665107.11
134 rdf:rest Nbdab92ae524542fbbddcf0eb99bffe09
135 N1504e7c3c34340d8a782c3312236a1fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Pyrazoles
137 rdf:type schema:DefinedTerm
138 N1cfe38c438dc4af4a7d1ff8fee56d610 schema:name dimensions_id
139 schema:value pub.1015219571
140 rdf:type schema:PropertyValue
141 N2c3f8dee29e84289a9c1ed2a0f2cf07f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 N2e06ed4ada3d45a3b43f51bbe9a20886 schema:name doi
145 schema:value 10.1007/s00432-010-0893-9
146 rdf:type schema:PropertyValue
147 N3577d8aad6b64dc586e6e351fe32423f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Sulfonamides
149 rdf:type schema:DefinedTerm
150 N365f08a88d864eeb8cd78cd59f028856 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Drug Resistance, Multiple
152 rdf:type schema:DefinedTerm
153 N3b25fe8190eb4495a68e6e5a9e3fd1bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Cyclooxygenase 2
155 rdf:type schema:DefinedTerm
156 N48041db8ef04470aa831ff710cf2581d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name ATP Binding Cassette Transporter, Subfamily G, Member 2
158 rdf:type schema:DefinedTerm
159 N5f523e20fe224de6babf60e8f656d7bd schema:issueNumber 2
160 rdf:type schema:PublicationIssue
161 N644a4351606841df92ece9f2d85eafef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Gene Expression Regulation, Neoplastic
163 rdf:type schema:DefinedTerm
164 N6de144d90d6f4e108cd558fea06a2a54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Female
166 rdf:type schema:DefinedTerm
167 N6e6717700980423080374713c2b8cfe5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Mitoxantrone
169 rdf:type schema:DefinedTerm
170 N718a9a651c4542a3a0a21137f3f06dd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Flow Cytometry
172 rdf:type schema:DefinedTerm
173 N76fd196b26da4571b134cf6ea3f1105a rdf:first sg:person.01354672317.51
174 rdf:rest N0d5bc583ea394cee9a57a6c0012a89f2
175 N870734c226a742b4987b71639ea168b7 schema:volumeNumber 137
176 rdf:type schema:PublicationVolume
177 N877eca01d96c41bea031824601877fd6 schema:name Springer Nature - SN SciGraph project
178 rdf:type schema:Organization
179 N91ba7dea361940b9845fd17b5634aaf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Gene Expression Regulation, Enzymologic
181 rdf:type schema:DefinedTerm
182 N95eca40a206e461ab07e44668a0c3826 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Cell Proliferation
184 rdf:type schema:DefinedTerm
185 Na9d4b8c120c94a9c8c0ca38119bd3acb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name ATP-Binding Cassette Transporters
187 rdf:type schema:DefinedTerm
188 Nb1216e3829b74312a5aa2cfc6d1aa1d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Antineoplastic Agents
190 rdf:type schema:DefinedTerm
191 Nb798cd2b01c04478ad35757baadb354e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Cyclooxygenase 2 Inhibitors
193 rdf:type schema:DefinedTerm
194 Nbdab92ae524542fbbddcf0eb99bffe09 rdf:first sg:person.01245756105.18
195 rdf:rest rdf:nil
196 Nc52563a953174dc0a3be37d65bf1ae6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Cell Line, Tumor
198 rdf:type schema:DefinedTerm
199 Nd5c5dcae4c644ce9a1d0ded13384d8fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Breast Neoplasms
201 rdf:type schema:DefinedTerm
202 Ne7b33c22b54d4d6eb529d711b9cbfe02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Neoplasm Proteins
204 rdf:type schema:DefinedTerm
205 Ne8ef4e029680445f8393bd87ace69792 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Celecoxib
207 rdf:type schema:DefinedTerm
208 Nf90d29da54e64ad8a563571161482bcf schema:name pubmed_id
209 schema:value 20422426
210 rdf:type schema:PropertyValue
211 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
212 schema:name Medical and Health Sciences
213 rdf:type schema:DefinedTerm
214 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
215 schema:name Oncology and Carcinogenesis
216 rdf:type schema:DefinedTerm
217 sg:journal.1313647 schema:issn 0171-5216
218 1432-1335
219 schema:name Journal of Cancer Research and Clinical Oncology
220 schema:publisher Springer Nature
221 rdf:type schema:Periodical
222 sg:person.01245756105.18 schema:affiliation grid-institutes:grid.411583.a
223 schema:familyName Behravan
224 schema:givenName Javad
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245756105.18
226 rdf:type schema:Person
227 sg:person.01322665107.11 schema:affiliation grid-institutes:grid.411583.a
228 schema:familyName Elahian
229 schema:givenName Fatemeh
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322665107.11
231 rdf:type schema:Person
232 sg:person.01354672317.51 schema:affiliation grid-institutes:grid.411583.a
233 schema:familyName Kalalinia
234 schema:givenName Fatemeh
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354672317.51
236 rdf:type schema:Person
237 sg:pub.10.1038/sj.onc.1202218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036542534
238 https://doi.org/10.1038/sj.onc.1202218
239 rdf:type schema:CreativeWork
240 sg:pub.10.1038/sj.onc.1206938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036684086
241 https://doi.org/10.1038/sj.onc.1206938
242 rdf:type schema:CreativeWork
243 sg:pub.10.1186/1475-2867-5-30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003230076
244 https://doi.org/10.1186/1475-2867-5-30
245 rdf:type schema:CreativeWork
246 sg:pub.10.1208/aapsj070112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032127936
247 https://doi.org/10.1208/aapsj070112
248 rdf:type schema:CreativeWork
249 grid-institutes:grid.411583.a schema:alternateName Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran
250 schema:name Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
251 Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P. O. Box 91775-1365, Mashhad, Iran
252 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...